Literature DB >> 9002520

Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation.

L Arvanitakis1, E Geras-Raaka, A Varma, M C Gershengorn, E Cesarman.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8, or HHV 8) is a virus that is consistently present in Kaposi's sarcoma and in primary-effusion (body-cavity-based) lymphomas, malignancies that occur frequently, but not exclusively, in AIDS patients. KSHV is a gamma herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus, both of which can transform lymphocytes. Cloning of a KSHV genome fragment revealed the presence of an open reading frame encoding a putative G-protein-coupled receptor that is homologous to a G-protein-coupled receptor encoded by herpesvirus Saimiri and to human interleukin-8 receptors. Here we show that the KSHV G-protein-coupled receptor is a bona fide signalling receptor which has constitutive (agonist-independent) activity in the phosphoinositide-inositoltrisphosphate-protein kinase C pathway. Furthermore, the KSHV G-protein-coupled receptor stimulates cellular proliferation, making it a candidate viral oncogene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002520     DOI: 10.1038/385347a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  188 in total

1.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins.

Authors:  D S Bellows; B N Chau; P Lee; Y Lazebnik; W H Burns; J M Hardwick
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 3.  Herpesvirus homologues of cellular genes.

Authors:  M Raftery; A Müller; G Schönrich
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

4.  Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor.

Authors:  Rizwan Masood; Ethel Cesarman; D Lynne Smith; Parkash S Gill; Ornella Flore
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells.

Authors:  Mark Cannon; Nicola J Philpott; Ethel Cesarman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures.

Authors:  D M Ciufo; J S Cannon; L J Poole; F Y Wu; P Murray; R F Ambinder; G S Hayward
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Complete sequence and genomic analysis of murine gammaherpesvirus 68.

Authors:  H W Virgin; P Latreille; P Wamsley; K Hallsworth; K E Weck; A J Dal Canto; S H Speck
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

8.  Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor.

Authors:  M Li; B Damania; X Alvarez; V Ogryzko; K Ozato; J U Jung
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

9.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

Review 10.  Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.

Authors:  Silvia Montaner; Irina Kufareva; Ruben Abagyan; J Silvio Gutkind
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-22       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.